Michael Gunnar  Knell net worth and biography

Michael Knell Biography and Net Worth

Michael G. Knell joined Charles River in April 2017 as Corporate Senior Vice President and Chief Accounting Officer. In this role, Mr. Knell is responsible for providing strategic guidance to the finance groups, including direction of the Global Accounting and Tax functions; maintaining Charles River's fiscal records; and preparing its financial reports. He also oversees the design and operation of the Company’s system of internal controls, ensuring compliance with the rules and regulations of the Sarbanes-Oxley Act.

Prior to joining Charles River, Mr. Knell served as the Chief Accounting Officer and Vice President of Finance at Bruker Corporation from 2012 to 2017. Mr. Knell was with Ernst & Young LLP in its Boston office from 1998 until 2011, where he served in various roles including Partner - Assurance Services. His audit experience at Ernst & Young included service for a variety of clients in the retail, consumer products, and manufacturing industries.

Mr. Knell is a Certified Public Accountant in Massachusetts and holds a B.S. degree in Business Administration from the State University of New York at Buffalo.

What is Michael Gunnar Knell's net worth?

The estimated net worth of Michael Gunnar Knell is at least $2.68 million as of August 10th, 2023. Mr. Knell owns 9,940 shares of Charles River Laboratories International stock worth more than $2,677,538 as of March 28th. This net worth approximation does not reflect any other investments that Mr. Knell may own. Learn More about Michael Gunnar Knell's net worth.

How old is Michael Gunnar Knell?

Mr. Knell is currently 47 years old. There are 5 older executives and no younger executives at Charles River Laboratories International. The oldest executive at Charles River Laboratories International is Mr. James C. Foster J.D., Chairman, CEO & President, who is 73 years old. Learn More on Michael Gunnar Knell's age.

How do I contact Michael Gunnar Knell?

The corporate mailing address for Mr. Knell and other Charles River Laboratories International executives is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. Charles River Laboratories International can also be reached via phone at (781) 222-6000 and via email at [email protected]. Learn More on Michael Gunnar Knell's contact information.

Has Michael Gunnar Knell been buying or selling shares of Charles River Laboratories International?

Michael Gunnar Knell has not been actively trading shares of Charles River Laboratories International in the last ninety days. Most recently, Michael Gunnar Knell sold 1,471 shares of the business's stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $216.54, for a transaction totalling $318,530.34. Following the completion of the sale, the chief accounting officer now directly owns 9,940 shares of the company's stock, valued at $2,152,407.60. Learn More on Michael Gunnar Knell's trading history.

Who are Charles River Laboratories International's active insiders?

Charles River Laboratories International's insider roster includes William Barbo (VP), Robert Bertolini (Director), Stephen Chubb (Director), Victoria Creamer (EVP), James Foster (CEO), Birgit Girshick (VP), Michael Knell (CAO), Deborah Kochevar (Director), Joseph LaPlume (EVP), George Massaro (Director), Shannon Parisotto (EVP), David Smith (CFO), and Richard Wallman (Director). Learn More on Charles River Laboratories International's active insiders.

Are insiders buying or selling shares of Charles River Laboratories International?

During the last year, Charles River Laboratories International insiders bought shares 3 times. They purchased a total of 7,942 shares worth more than $1,447,729.04. During the last year, insiders at the medical research company sold shares 7 times. They sold a total of 23,211 shares worth more than $5,481,396.41. The most recent insider tranaction occured on February, 29th when EVP Victoria L Creamer sold 5,000 shares worth more than $1,268,500.00. Insiders at Charles River Laboratories International own 1.3% of the company. Learn More about insider trades at Charles River Laboratories International.

Information on this page was last updated on 2/29/2024.

Michael Gunnar Knell Insider Trading History at Charles River Laboratories International

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/10/2023Sell1,471$216.54$318,530.349,940View SEC Filing Icon  
11/16/2022Sell855$248.59$212,544.456,438View SEC Filing Icon  
6/3/2021Sell800$329.76$263,808.004,563View SEC Filing Icon  
2/19/2021Sell410$290.99$119,305.904,198View SEC Filing Icon  
See Full Table

Michael Gunnar Knell Buying and Selling Activity at Charles River Laboratories International

This chart shows Michael Gunnar Knell's buying and selling at Charles River Laboratories International by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Charles River Laboratories International Company Overview

Charles River Laboratories International logo
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More

Today's Range

Now: $270.65
Low: $267.23
High: $270.98

50 Day Range

MA: $242.91
Low: $206.11
High: $273.43

2 Week Range

Now: $270.65
Low: $161.65
High: $275.00

Volume

131,115 shs

Average Volume

561,118 shs

Market Capitalization

$13.88 billion

P/E Ratio

29.39

Dividend Yield

N/A

Beta

1.39